Kairos Pharma, Ltd. /
Celyn Therapeutics, Inc.
Kairos Pharma agrees to buy CL-273 from Celyn
Source for the buyer and target: Kairos Pharma, Ltd.
For the buyer and target.
“Los Angeles, CA – March, 02, 2026 – Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment.”
Published 2 Mar 2026
Open the sourceWhat happened
Kairos Pharma signed a binding term sheet with Celyn Therapeutics for a proposed asset acquisition of the EGFR inhibitor CL-273. The deal is not final, and the parties must sign a definitive agreement before the purchase can proceed. [01]
Under the term sheet, Celyn would receive shares equal to 16.5% of Kairos Pharma on a fully diluted basis, a $15 million milestone tied to an FDA submission, and a 2% royalty on U.S. net revenues. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Kairos Pharma agrees to buy CL-273 from Celyn
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly